Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie.
Knoedler M, Gauler TC, Gruenwald V, Matzdorff A, Schroeder M, Dietz A, Jordan WO, Arnold D, Hennemann B, Hofele C, Weissinger F, Eberhardt W, Keilholz U. Knoedler M, et al. Oncology. 2013;84(5):284-9. doi: 10.1159/000345453. Epub 2013 Feb 26. Oncology. 2013. PMID: 23445718 Clinical Trial.
Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108).
Klinghammer K, Gauler T, Dietz A, Grünwald V, Stöhlmacher J, Knipping S, Schroeder M, Guntinas-Lichius O, Frickhofen N, Lindeman HW, Fietkau R, Haxel B, Große-Thie C, Maschmeyer G, Zipfel M, Martus P, Knoedler M, Keilholz U. Klinghammer K, et al. Among authors: knoedler m. Eur J Cancer. 2019 Nov;122:53-60. doi: 10.1016/j.ejca.2019.08.018. Epub 2019 Oct 13. Eur J Cancer. 2019. PMID: 31618704 Clinical Trial.
Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID Trial.
Goerling U, Gauler T, Dietz A, Grünwald V, Knipping S, Guntinas-Lichius O, Frickhofen N, Lindeman HW, Fietkau R, Haxel B, Große-Thie C, Maschmeyer G, Zipfel M, Martus P, Knoedler M, Keilholz U, Klinghammer K. Goerling U, et al. Among authors: knoedler m. Oncol Res Treat. 2022;45(6):319-325. doi: 10.1159/000521415. Epub 2021 Dec 10. Oncol Res Treat. 2022. PMID: 34915492 Free article. Clinical Trial.
First-in-man dose escalation and pharmacokinetic study of CAP7.1, a novel prodrug of etoposide, in adults with refractory solid tumours.
Keilholz U, Rohde L, Mehlitz P, Knoedler M, Schmittel A, Kümmerlen V, Klinghammer K, Treasure P, Lassus M, Steventon G, Machacek M, Utku N. Keilholz U, et al. Among authors: knoedler m. Eur J Cancer. 2017 Jul;80:14-25. doi: 10.1016/j.ejca.2017.03.032. Epub 2017 May 19. Eur J Cancer. 2017. PMID: 28531881 Clinical Trial.
CMV-specific central memory T cells reside in bone marrow.
Letsch A, Knoedler M, Na IK, Kern F, Asemissen AM, Keilholz U, Loesch M, Thiel E, Volk HD, Scheibenbogen C. Letsch A, et al. Among authors: knoedler m. Eur J Immunol. 2007 Nov;37(11):3063-8. doi: 10.1002/eji.200636930. Eur J Immunol. 2007. PMID: 17960663 Free article.
37 results